<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949948</url>
  </required_header>
  <id_info>
    <org_study_id>REK 2011/2435</org_study_id>
    <nct_id>NCT01949948</nct_id>
  </id_info>
  <brief_title>Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke</brief_title>
  <acronym>NOR-TEST</acronym>
  <official_title>Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lars Thomassen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Alteplase dissolves blood vessel clots in acute ischemic stroke and is the only&#xD;
      approved acute drug treatment &lt;4½ hours of stroke onset. The overall benefit from alteplase&#xD;
      is substantial, but up to 2/3 of patients with large artery clots may not achieve reopening&#xD;
      of the vessel and up to 40% of the patients may remain severely disabled or die, leaving&#xD;
      substantial room for improvement. Tenecteplase, widely used in coronary heart disease, may be&#xD;
      more effective and may have less bleeding complications than alteplase, and may be the drug&#xD;
      of choice also in stroke.&#xD;
&#xD;
      HYPOTHESIS: Tenecteplase may be given safely to patients with acute ischemic stroke at a dose&#xD;
      that is associated with improved clinical outcome compared with existing treatment options.&#xD;
&#xD;
      AIMS: To compare efficacy and safety of tenecteplase vs. alteplase given &lt;4½ hours after&#xD;
      symptom onset.&#xD;
&#xD;
      STUDY ENDPOINTS: The primary study endpoint is excellent clinical outcome at 3 months&#xD;
      (effect). Secondary study endpoints are major early clinical improvement (effect) and&#xD;
      bleeding complications (safety).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESIS: 1) Tenecteplase 0.4 mg/kg may be given safely to patients with acute ischaemic&#xD;
      stroke &lt;4½ hours after stroke onset. 2) Tenecteplase 0,4 mg/kg (single bolus)has superior&#xD;
      efficacy and safety compared with alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes)&#xD;
      when given within 4 ½ hours after stroke onset.&#xD;
&#xD;
      DESIGN: NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded&#xD;
      endpoint) trial with randomisation tenecteplase:alteplase 1:1.&#xD;
&#xD;
      POWER CALCULATION: NOR-TEST aims at detecting a 9 % higher percentage excellent outcome with&#xD;
      tenecteplase vs. alteplase (r1=0.40; r2=0.49; OR 1.44; power 0.8), and will include 954&#xD;
      patients during 3 years.&#xD;
&#xD;
      PATIENT RECRUITMENT: All patients found eligible for thrombolytic therapy are eligible for&#xD;
      NOR-TEST, i.e. NOR-TEST changes neither inclusion nor exclusion criteria. The number of&#xD;
      patients treated at a participating centre will therefore essentially remain unchanged.&#xD;
      Estimated 400 patients are thrombolysed per year in participating centres. Allowing for 20%&#xD;
      of patients not being included in NOR-TEST, the total number of patients (n=954) will still&#xD;
      be met.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical: Functional handicap</measure>
    <time_frame>90 days</time_frame>
    <description>Excellent outcome defined as mRS 0-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic cerebral hemorrhage</measure>
    <time_frame>24-36 hours</time_frame>
    <description>Haemorrhagic transformation (haemorrhagic infarct / haematoma) as defined by CT (or MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic transformation</measure>
    <time_frame>24-36 hours</time_frame>
    <description>Any hemorrhagic infarct or parenchymal hematoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological improvement</measure>
    <time_frame>24 hours</time_frame>
    <description>NIHSS changes from baseline: NIHSS=0 or reduction of ≥4 NIHSS points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical: Functional handicap</measure>
    <time_frame>90 days</time_frame>
    <description>Ordinal shift analysis of mRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>90 days</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Tenecteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.4 mg/kg single bolus intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>0.4 mg/kg single bolus intravenously</description>
    <arm_group_label>Tenecteplase</arm_group_label>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase</intervention_name>
    <description>0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously</description>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Actilyse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Ischaemic stroke with measurable deficit on NIH Stroke Scale&#xD;
&#xD;
          -  All stroke sub-types, severities and vascular distributions,a visible arterial&#xD;
             occlusion is not required for inclusion&#xD;
&#xD;
          -  Treatment within 4 ½ hours of stroke onset&#xD;
&#xD;
          -  Patients awakening with symptoms are defined by the time last observed normal and&#xD;
             awake&#xD;
&#xD;
          -  Informed written consent signed by the patient, verbal consent from the patients as&#xD;
             witnessed by a non-participating health care person, or consent by the signature of&#xD;
             the patient's family must be provided&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with premorbid modified Rankin Scale (mRS) score ≥3&#xD;
&#xD;
          -  Patients for whom a complete NIH Stroke Score cannot be obtained&#xD;
&#xD;
          -  Hemiplegic migraine with no arterial occlusion on CTA&#xD;
&#xD;
          -  Seizure at stroke onset and no visible occlusion on baseline CTA&#xD;
&#xD;
          -  Intracranial haemorrhage on baseline CT&#xD;
&#xD;
          -  Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is&#xD;
             normal&#xD;
&#xD;
          -  Large areas of hypodense ischaemic changes on baseline CT&#xD;
&#xD;
          -  Patients with systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;110 mm&#xD;
             Hg&#xD;
&#xD;
          -  Female, pregnant or breast feeding&#xD;
&#xD;
          -  Known bleeding diathesis&#xD;
&#xD;
          -  Use of oral anticoagulants and International Normalized Ratio (INR) ≥1,4&#xD;
&#xD;
          -  Use of new oral anticoagulants (NOAC) within the last 12 hours&#xD;
&#xD;
          -  Heparin &lt;48 hours and increased Activated partial thromboplastin tike (APTT)&#xD;
&#xD;
          -  Low molecular weight heparin(oid) &lt;24 hours&#xD;
&#xD;
          -  Any other investigational drug &lt;14 days&#xD;
&#xD;
          -  Sepsis&#xD;
&#xD;
          -  Patients with arterial puncture at a noncompressible site or lumbar puncture &lt;7 days&#xD;
&#xD;
          -  Major surgery or serious trauma &lt;14 days&#xD;
&#xD;
          -  Gastrointestinal or urinary tract hemorrhage &lt;14 days&#xD;
&#xD;
          -  Clinical stroke &lt;2 months&#xD;
&#xD;
          -  History of intracranial haemorrhage&#xD;
&#xD;
          -  Brain neurosurgery &lt;2 months&#xD;
&#xD;
          -  Serious head trauma &lt;2 months&#xD;
&#xD;
          -  Pericarditis&#xD;
&#xD;
          -  Any serious medical illness likely to interact with treatment&#xD;
&#xD;
          -  Confounding pre-existent neurological or psychiatric disease&#xD;
&#xD;
          -  Unlikely to complete follow-up&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Thomassen, MD PhD Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. Neurology, Haukeland University HospitalBergen, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrike Waje-Andreassen, MD PhD Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Dept. Neurology, Haukeland University Hospital, Bergen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Logallo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Neurology, Haukeland University Hospital, Bergen, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordland Hospital</name>
      <address>
        <city>Bodø</city>
        <zip>8092</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Førde Central Hospital</name>
      <address>
        <city>Førde</city>
        <zip>6800</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haugesund Hospital</name>
      <address>
        <city>Haugesund</city>
        <zip>5516</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molde Hospital</name>
      <address>
        <city>Molde</city>
        <zip>6400</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Nordbyhagen</city>
        <zip>1474</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ullevål University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baerum Hospital</name>
      <address>
        <city>Rud</city>
        <zip>1309</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Telemark Hospital</name>
      <address>
        <city>Skien</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hosital</name>
      <address>
        <city>Stavanger</city>
        <zip>4017</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olav Hospital NTNU</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tønsberg Hospital</name>
      <address>
        <city>Tønsberg</city>
        <zip>3100</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Logallo N, Kvistad CE, Nacu A, Naess H, Waje-Andreassen U, Asmuss J, Aamodt AH, Lund C, Kurz MW, Rønning OM, Salvesen R, Idicula TT, Thomassen L. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol. 2014 May 15;14:106. doi: 10.1186/1471-2377-14-106.</citation>
    <PMID>24886064</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 21, 2013</study_first_submitted>
  <study_first_submitted_qc>September 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Haukeland University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Thomassen</investigator_full_name>
    <investigator_title>Senior Consultant neurologist; Professor</investigator_title>
  </responsible_party>
  <keyword>treatment, intervention, thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 14, 2020</submitted>
    <returned>April 27, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

